Zacks Research Has Pessimistic Outlook of Pfizer Q4 Earnings

Pfizer Inc. (NYSE:PFE) – Investment analysts at Zacks Research decreased their Q4 2025 EPS estimates for Pfizer in a research note issued to investors on Tuesday, December 30th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $0.49 per share for the quarter, down from their prior estimate of $0.58. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer’s Q2 2026 earnings at $0.66 EPS and Q2 2027 earnings at $0.62 EPS.

PFE has been the topic of several other research reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Morgan Stanley decreased their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research note on Wednesday, November 5th. Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research report on Friday, October 31st. Finally, Citigroup began coverage on shares of Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $28.06.

Pfizer Stock Down 0.4%

Shares of PFE stock opened at $24.90 on Thursday. The stock’s 50 day simple moving average is $25.17 and its 200 day simple moving average is $24.90. Pfizer has a twelve month low of $20.92 and a twelve month high of $27.69. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The company has a market capitalization of $141.57 billion, a price-to-earnings ratio of 14.48 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio is 100.00%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Fiduciary Alliance LLC grew its stake in Pfizer by 46.4% in the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after acquiring an additional 46,043 shares during the period. Vista Investment Partners LLC raised its position in shares of Pfizer by 236.1% during the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock worth $1,774,000 after purchasing an additional 48,900 shares during the period. Westbourne Investments Inc. bought a new position in shares of Pfizer in the 1st quarter worth $2,411,000. Generali Investments CEE investicni spolecnost a.s. lifted its holdings in shares of Pfizer by 76.4% in the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock worth $2,784,000 after purchasing an additional 47,319 shares in the last quarter. Finally, Bourne Lent Asset Management Inc. grew its position in Pfizer by 90.8% in the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after purchasing an additional 18,200 shares during the period. Institutional investors own 68.36% of the company’s stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Zacks raised several upcoming quarterly EPS forecasts (notably Q2 2026/Q2 2027 estimates were increased modestly), which supports near‑term earnings visibility for PFE. Zacks research updates
• Positive Sentiment: Reports say Pfizer tops a list of drugmakers planning price hikes across hundreds of branded medications — this could help revenue stability if enacted. Pfizer tops list as drugmakers plan price hike
• Positive Sentiment: Analysis pieces argue Wall Street has “given up” too quickly and that with activist exits and stabilizing revenue Pfizer could be an undervalued value play — supportive for longer‑term buyers. Why Wall Street gave up on Pfizer—and why that may be a mistake
• Neutral Sentiment: Investor guides ask whether to buy Pfizer under $30, noting the pipeline could produce upside but gains may take time — useful context for value investors but not an immediate catalyst. Should You Buy Pfizer While It’s Under $30?
• Neutral Sentiment: Longer‑term think pieces examine where Pfizer might be in five years — these shape investor expectations but are speculative rather than immediate drivers. Where Will Pfizer Be in 5 Years?
• Neutral Sentiment: TD Cowen maintained a hold rating on PFE — reinforces cautious analyst posture and limits upside from upgrades. TD Cowen hold rating
• Negative Sentiment: Zacks lowered its Q4 2025 EPS estimate to $0.49 (from $0.58) in the same set of notes that raised other quarters — the cut highlights near‑term volatility in Pfizer’s revenue/earnings cadence. Zacks lowers Q4 2025 estimate
• Negative Sentiment: Multiple pieces emphasize Pfizer’s post‑COVID decline (stock down significantly from 2021 highs and multi‑year underperformance), keeping pressure on the share price until clearer growth materializes. The past three years for Pfizer investors has not been profitable

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.